Hypoglycemia in patients with type 2 diabetes is not often recognized as a risk with potential health consequences. Although the risk of hypoglycemia in patients with type 2 diabetes is not as great as that of patients with type 1 diabetes, the prevalence of type 2 diabetes is much greater, making it a clinically significant concern. As such, clinicians need to be aware of the hypoglycemic risk in patients with type 2 diabetes, as well as the immediate and long-term consequences of hypoglycemia. This article will review the prevalence of hypoglycemia in patients with type 2 diabetes, assess the consequences of hypoglycemia, discuss how to identify patients at risk of hypoglycemia, and provide an overview of diabetes management strategies aimed at lowering the risk of hypoglycemia.
symptoms, and it is generally accepted that a severe hypoglycemic event (HE) is one in which a patient is unable to self-treat and requires assistance, 6 regardless of the glucose level.
Pathophysiology of Hypoglycemia
The brain primarily uses glucose as a source of energy, but is unable to synthesize or store it; hence, it is vulnerable to hypoglycemia.
Physiological mechanisms that protect the brain from the effects of hypoglycemia, known as the counter-regulatory response (CRR) to hypoglycemia, involve the suppression of insulin release and activation of hormones such as glucagon and epinephrine that stimulate hepatic glucose production and inhibit peripheral glucose uptake. 9 These usually remain functional until an advanced disease state. In non-diabetic adults, this response to a fall in blood glucose levels, along with the onset of symptoms of hypoglycemia, occur at reproducible blood glucose thresholds (see Figure 1 ). Recurrent hypoglycemia impairs the ability of the brain to detect and initiate the CRR to subsequent hypoglycemia. 10 Although the physiology of the CRR is well understood, the underlying cellular mechanisms by which the brain senses hypoglycemia and initiates the CRR have only been elucidated in recent years. Absence of the glucagon response to falling plasma glucose concentrations plays a key role in the pathogenesis of hypoglycemia. 11 During hypoglycemia, central and peripheral glucose sensors detect declining glucose levels and initiate the CRR. Recent studies have found that impairment of the CRR is accompanied by a deficient response of ventromedial hypothalamic glucose-inhibited neurons to decreased glucose levels. Nitric oxide (NO) production in the ventromedial hypothalamus is critical for both the CRR and glucose sensing by glucose-inhibited neurons.
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Prevalence of Hypoglycemia in Type 2 Diabetes
Since there is little consistency among diabetes studies regarding the definition of hypoglycemia, assessments of the prevalence of hypoglycemia among patients with type 2 diabetes should be interpreted with caution. A prevalence of 3.1 % was reported in a recent large sample cohort of 860,845 patients. [17] [18] [19] [20] [21] [22] Other reported prevalence data include 8.8 % in older patients (mean age 65, n=16,667); 22 34 % in self-reported patients treated with metformin and a sulfonylurea for at least six months (n=400); 21 between 12 % using diet alone, and 30 % using insulin, in a study in which hypoglycemia was defined as typical symptoms relieved by eating and/or blood glucose level <59.4 mg/dl; 19 and 63 % (46 % mild, 37 % moderate, 13 % severe, and 4 % very severe) in a study in which patients were treated with oral antihyperglycemic drugs (OADs) and episodes of hypoglycemia were self-reported. 18 The wide range of the reported incidence illustrates the difficulty in assessing the prevalence of hypoglycemia. Variables include the type of hypoglycemia (for example, hypoglycemia requiring medical intervention versus mild hypoglycemia self-defined by the patient), as well as different study durations, treatment regimens, disease duration, and patient characteristics. These studies also fail to take into account nocturnal HEs, for which reported data are often sparse and imprecise. 23 Nocturnal hypoglycemia is likely to be underreported and is particularly dangerous because patients are unlikely to recognize symptoms or awaken during an episode.
Health Impact of Hypoglycemia
A recent literature review highlighted the potential impact of hypoglycemia on the lives of people with type 2 diabetes, including depression, heightened anxiety, and impairment of the ability to drive, work, and function in ways that are important for quality of life (QoL).
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Mild hypoglycemia does not have serious clinical effects, other than the potential to induce defects in the CRR and impaired awareness of subsequent HEs. 6 However, even clinically trivial events may reduce adherence to therapeutic regimens. 6 Severe HEs have serious clinical consequences, particularly in elderly patients with diabetes. A prospective study of patients aged >80 years with well-controlled type 2 diabetes reported that hypoglycemia was responsible for 25 % of hospitalizations associated with diabetes. 25 It has also been associated with behavioral changes, cognitive impairment, seizures, coma, and a mortality rate estimated at between 4.9 and 9 %. 6, 18 In Fear of hypoglycemia imposes an additional psychological burden. A US study assessed QoL according to the US-weighted summary score (utility) and worry subscale of the Hypoglycemia Fear Survey (HFS). The subscale comprises 18 questions that measure degree of patient fear in the past six months, and is scaled from 0 to 72 (from least to most worry). The EuroQoL-5D Questionnaire, a non-disease-specific instrument for assessing health-related QoL, was also administered.
The unweighted summary scores were transformed into US preference-weighted index scores, -0.038-1.0, for the purposes of this study. Patients who reported HEs had a significantly lower mean utility score (0.78 versus 0.86, p<0.0001) and significantly higher mean HFS score (17.5 versus 6.2, p<0.0001) than those who did not report HEs. Differences in mean scores between those with and without HEs increased with the level of severity. 35 The magnitude of fear of hypoglycemia is associated with the severity and frequency of HEs.
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Economic Impact of Hypoglycemia
The economic impact of HEs in patients with type 2 diabetes is substantial (see Figure 2) . A Swedish study estimated the direct and Table 1 ). Among respondents who experienced an HE at work (n=972), 18.3 % missed work for a mean duration of 9.9 hours. Among those who had HEs outside working hours (including nocturnally), 22.7 % arrived late for work or missed a full day.
Nocturnal HEs had the greatest impact on productivity loss, with an average of 14.7 working hours lost. 42 Hypoglycemia also represents a considerable economic burden in terms of healthcare systems. Reported costs of a severe HE varied from The incidence of HEs is highest in older patients with poor glycemic control. 49 In the UK prospective diabetes study (UKPDS), the rate of severe hypoglycemia rose once the known diabetes duration exceeded nine years. 50 Factors that may increase the likelihood of hypoglycemia include duration of diabetes, presence of other comorbidities, renal impairment, loss of residual insulin secretion, defective counter-regulation, weight gain in the last 12 months, microvascular complications, and specific cardiovascular conditions (angina, heart attack, stroke, peripheral vascular disease, or congestive heart failure). 6, 18 The UKPDS found the highest incidence of hypoglycemia in patients with type 2 diabetes who used insulin. 50 Some of these factors are interrelated, as increasing diabetes duration is invariably associated with increasing age and increasing loss of endogenous insulin secretion.
The most common cause of hypoglycemia in type 2 diabetes is iatrogenic, occurring with the use of insulin secretagogues and insulin therapy. 44, 51 These can overwhelm the normal physiological response to a fall in plasma glucose, primarily by preventing a corresponding drop in circulating insulin. Defects in glucagon and other stress responses develop during type 2 diabetes and these are worsened by specific therapies, such as sulfonylurea drugs, which sustain intrapancreatic insulin levels during hypoglycemia. 
Diabetes Management Strategies that Mitigate Hypoglycemia
According to the ADA and European Association for the Study of Diabetes (EASD) joint consensus statement, the first approach to type 2 diabetes treatment should be intervention at the time of diagnosis with metformin in combination with lifestyle changes, followed by augmentation of therapy with additional agents as a means of achieving and maintaining recommended levels of glycemic control. 53 Appropriate targeting of plasma glucose may help patients and practitioners achieve glycosylated hemoglobin (HbA 1c ) goals, reduce excessive self-testing, and minimize the occurrence of HEs. 54 Subset analyses from the Action to control cardiovascular risk in diabetes (ACCORD) trial demonstrated that the lowest risk of mortality was related to lower mean levels of HbA 1c with the intensive therapy strategy. Risk of death increased steadily as mean levels increased from 6 % to 9 %. The minority subgroup of patients in the intensive therapy group who had HbA 1c levels higher than 7 % accounted for the excess risk associated with that therapy regimen. Therefore, trying to lower the HbA 1c level to less than 7 % with intensive treatment in therapy-resistant individuals may be detrimental. [55] [56] [57] Basically, an HbA 1c goal of less than 7 % remains recommended, although goals should be individualized for selected patients. Unrecognized hypoglycemia and weight gain in the ACCORD study were also likely major contribuors to its adverse outcomes. 58 Earlier and more intensive intervention when a patient is not experiencing severe HEs, rather than waiting for an increase in HbA 1c
and then intensifying glucose control, may improve the glycemic profile by avoiding prolonged periods of hyperglycemia. 59 Periods of glycemic exposure may be avoided by transitioning earlier to more intensive glucose therapy, instead of waiting for a rise in HbA 1c and then increasing glucose control. Intensive glucose control has demonstrated advantages, such as lowering the risk of non-fatal MI; however, it may also increase the risk of severe hypoglycemia. [60] [61] [62] [63] A meta-analysis of the effect of intensive glucose control on cardiovascular outcomes in individuals with type 2 diabetes found that a higher proportion of patients on intensive therapy than standard treatment had a hypoglycemic episode. Severe hypoglycemia was much less frequent than non-severe hypoglycemia; however, nearly twice as many patients on intensive therapy compared with those on standard treatment had a severe HE.
Additionally, patients receiving intensive therapy were a mean of 2.5 kg heavier than those on standard treatment by the end of the study. 64 A major challenge in the management of HEs in patients with type 2 diabetes is hypoglycemic unawareness, which is caused by deficient epinephrine response and characterized by a progressive loss of the autonomic symptoms of hypoglycemia, such as sweating, tremor, and palpitations, together with a reduced response of glucagon and epinephrine to falling levels of blood glucose. 15, 16 As a result, patients are unaware of the problem until they have central nervous system dysfunction and may not be able to appropriately respond to the hypoglycemia. Hypoglycemic unawareness is associated with a high risk of more severe HEs that may result in seizures and coma. 65 However, the condition is reversible to some extent and several strategies for managing hypoglycemic unawareness exist, such as strict avoidance of HEs for two to three weeks and optimizing insulin treatment (see Table 2 ).
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Metformin often fails to maintain glycemic control over the long term, because disease progression is accompanied by a progressive decline in insulin-secreting β-cell function, which begins early in the disease course, and an impaired incretin response. After five years, metformin has been shown to have a 21 % failure rate. 67 The ADA and EASD recommend that patients who fail to achieve glycemic control on metformin should consider alternative regimens, including concomitant treatment with a sulfonylurea or insulin. 53, 68 However, effective insulin treatment is often delayed because of perceived fear of hypoglycemia.
Insulin has traditionally been considered a last resort for patients who fail to maintain glycemic control with diet and OADs. A recent study compared insulin-based therapy with an oral therapy-based treatment regimen in patients with newly diagnosed type 2 diabetes. Insulin-based therapy was found to be equivalent to oral-based therapy in terms of efficacy, weight gain, frequency of HEs, compliance, treatment satisfaction, and QoL. 69 Insulin is also thought to protect against the decline in β-cell function, therefore conferring a disease-modifying effect. 70 Recently developed insulin analogs have more predictable onsets and durations of action than human insulin formulations and more closely approximate the physiological action profile of endogenous insulin. Rapid-acting analogs have a more rapid onset 
Conclusion
Hypoglycemia has serious clinical, social, and economic consequences, and its occurrence in type 2 diabetes is likely to escalate along with the increase in disease prevalence, as more patients reach the insulin-defective stage of the disease. Hypoglycemia is not just the result of insulin use; in fact, most hypoglycemia is seen in patients using OADs. Treatment selection, as well as glycemic targets, should be customized based on each patient's individual risk of hypoglycemia.
Recent advances in diabetes therapy allow for lower blood glucose levels to be more intensively and successfully targeted, while reducing the risk of hypoglycemia. This should result in better adherence to therapy and improved clinical, health economics and QoL outcomes. n Hypoglycemia in Type 2 Diabetes-Consequences and Risk Assessment
